Summary

Eligibility
for people ages 57-87 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
Peter Ljubenkov

Description

Summary

The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with early AD.

Official Title

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease

Keywords

Alzheimer's Disease Alzheimer Disease ABBV-8E12 ABBV-8E12 Dose 1 ABBV-8E12 Dose 2

Eligibility

You can join if…

Open to people ages 57-87

  • All subjects with early AD who complete Study M15-566 (NCT02880956), meet all inclusion criteria, and do not meet any

You CAN'T join if...

are eligible for enrollment

  • Subject was compliant during participation in Study M15-566 (NCT02880956)
  • Subject has an identified, reliable study partner who has frequent contact with the subject and who will provide information as to the subject's cognitive and functional abilities

Exclusion Criteria:

  • The subject has any significant change in his/her medical condition since participation in Study M15-566 (NCT02880956) that could interfere with the subject's participation in Study M15-570, could place the subject at increased risk, or could confound interpretation of study results
  • More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15-566 (NCT02880956)
  • The subject is concurrently enrolled in another interventional clinical study involving a therapeutic agent with the exception of Study M15-566 (NCT02880956)

Locations

  • University of California, San /ID# 204011
    San Francisco California 94143-0633 United States
  • Irvine Clinical Research /ID# 204000
    Irvine California 92614 United States

Lead Scientist at UCSF

  • Peter Ljubenkov
    Assistant Professor, Neurology. Authored (or co-authored) 15 research publications.

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03712787
Phase
Phase 2
Study Type
Interventional
Last Updated